Table. Baseline Characteristics of Study Population.
| Characteristic | No. (%) | |
|---|---|---|
| Alert group (n = 1590) | Usual care (n = 1534) | |
| Age, median (IQR), y | 76.5 (65-86) | 77 (65-86) |
| Sex | ||
| Male | 794 (49.9) | 746 (48.6) |
| Female | 796 (50.1) | 788 (51.4) |
| Race and ethnicity | ||
| Asian | 13 (0.8) | 11 (1.4) |
| Black | 324 (20.4) | 298 (19.4) |
| Hispanic | 136 (8.6) | 162 (10.6) |
| Non-Hispanic | 1448 (91.1) | 1359 (88.6) |
| White | 1126 (70.8) | 1077 (70.2) |
| Other ethnicity | 6 (0.4) | 13 (0.9) |
| Other race | 127 (8.0) | 137 (8.9) |
| LVEF, median (IQR), % | 55 (37.5-62.5) | 55 (37.5-62.5) |
| LVEF ≤40% | 367 (23.1) | 359 (23.4) |
| NT-proBNP, median (IQR), pg/mL | 3826 (1692-8241) | 3867 (1663-8917) |
| Creatinine, median (IQR), mg/dL | 1.3 (0.9-2.0) | 1.3 (0.9-1.9) |
| Serum sodium, median (IQR), mmol/L | 139 (136-141) | 139 (136-141) |
| COVID+ | 199 (12.5) | 189 (12.3) |
| Medical history and admission location | ||
| Atrial fibrillation | 773 (48.6) | 778 (50.7) |
| Chronic kidney disease | 659 (41.4) | 623 (40.6) |
| Chronic obstructive pulmonary disease | 478 (30.1) | 475 (31.0) |
| Type 2 diabetes | 694 (43.6) | 670 (43.7) |
| Depression | 375 (23.6) | 374 (24.4) |
| ICU admission | 284 (17.9) | 270 (17.6) |
| Medications | ||
| ACE-I/ARB/ARNI | 766 (48.2) | 738 (48.1) |
| β-Blocker | 1307 (82.2) | 1264 (82.4) |
| Aldosterone blocker | 376 (23.6) | 385 (25.1) |
| SGLT2i | 138 (8.7) | 134 (8.7) |
| Loop diuretic | 1588 (99.9) | 1532 (99.9) |
| ICD/CRT | 235 (14.8) | 235 (15.3) |
| Risk categories at time of randomization | ||
| Very low risk (<5%) | 425 (26.7) | 360 (23.5) |
| Low risk (5%-15%) | 752 (47.3) | 770 (50.2) |
| Medium risk (15%-30%) | 307 (19.3) | 319 (20.8) |
| High risk (30%-50%) | 96 (6.0) | 77 (5.0) |
| Very high risk (>50%) | 10 (0.6) | 8 (0.5) |
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; CRT, cardiac resynchronization therapy; ICD; implantable cardioverter-defibrillator; ICU, intensive care unit; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro–brain natriuretic peptide; SGLT2i, sodium/glucose cotransporter 2 inhibitor.